LCT updates Diabecell trial
Wednesday, 11 February, 2009
Auckland’s Living Cell Technologies (LCT) has reported long-term follow-up results from seven patients implanted with its porcine islet product Diabecell in a Phase I/IIa trial in Russia.
Five patients who received double low-dose implants showed no safety concerns and maintained good blood glucose control. The other two patients on a single higher-dose implant also reported no safety concerns, the company said.
LCT’s medical director Professor Bob Elliott said none of the patients had problems with clinically relevant episodes of low blood glucose.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
